【摘要】：目的將成分單采技術用于預存式自體輸血,評估其在成分式預存自體輸血中的安全性、有效性。方法以普外科、骨科的擇期手術患者中符合預存式自體輸血指證患者109例為研究對象,分析比較術前采集自體全血、成分單采自體紅細胞及未進行自體血預存的3組患者,術前、術后1 d、3 d Hb、Hct、Plt變化,及術后異體血輸注率、術后平均住院日等指標,評價預存式自體成分輸血的有效性。結果自體成分血組患者術后1 d、3 d Hb(117.66±18.02)g/L vs.(118.4±16.79)g/L vs.(143.6±10.96)g/L,P0.05;Hct(36.26±4.63)%vs.(36.24±4.85)%vs.(43.17±3.15)%,P0.05;Plt(201.29±58.09)×109/L vs.(202.28±48.06)×109/L vs.(240.11±72.29)×109/L,P0.05均較術前下降;與術前比較自體全血組患者術后1 d、3 d Hb(139.43±12.11)g/L vs.(114.93±15.87)g/L vs.(112.72±17.9)g/L,P0.05;Hct(42.45±3.08)%vs.(35.73±4.3)%vs.(34.08±5.44)%,P0.05;Plt(242.36±56.25)×109/L vs.(205.84±65.73)×109/L vs.(197.89±54.71)×109/L,P0.05均降低;對照組術后1 d、3 d較術前Hb(117.7±18.42)g/L vs.(112.62±18.2)g/L vs.(139.97±11.12)g/L,P0.05;Hct(35.33±5.26)%vs.(33.73±5.42)%vs.(42.33±3.86)%,P0.05;Plt(166.27±57.74)×109/L vs.(154.08±55.75)×109/L vs.(216.13±82.21)×109/L,P0.05均降低,但3組患者術后Hb110 g/L,Hct≥33%。3組患者術后1 d、3 d Hb、Hct變化差異無統(tǒng)計學意義(P0.05),自體成分血組及自體全血組術后1 d、3 d Plt高于對照組(P0.05)。自體成分血組與對照組比較有效縮短了術后平均住院日(17.93±7.13)d,(13.09±5.58)d,P0.05,與自體全血組比較差異無統(tǒng)計學意義(13.09±5.58)d,(14.39±5.13)d,P0.05。自體成分血組患者的異體血輸注率與自體全血組比較差異無統(tǒng)計學意義(11.4%,22.7%,P0.05)。結論將成分單采技術用于自體成分血輸注,有利于縮短平均住院時間,降低異體血輸注率,此技術用于自體成分輸血具有可行性,安全有效。
[Abstract]:Objective to evaluate the safety and effectiveness of single component autotransfusion in preexisting autologous blood transfusion. Methods 109 patients with preexisting autologous blood transfusion in general surgery and orthopedic department were studied. The autologous whole blood was collected before operation, autologous erythrocyte was collected alone and autologous blood was not pre-stored. Before and 1 day after operation, the changes of Hb HctTX Plt, the rate of allogeneic blood transfusion, and the average hospitalization days after operation were evaluated to evaluate the efficacy of pre-stored autogenous component transfusion. 緇撴灉鑷綋鎴愬垎琛，

本文編號：2145516